Oncology

In this month’s “Hot Topic,” Alicia Algeciras-Schimnich, Ph.D., will provide you with valuable information regarding the utility of the prostate specific antigen test, and how the calculation of a prostate health index, or phi, can help to stratify a patient’s risk for prostate cancer and reduce unnecessary biopsies.

By Alicia Algeciras-Schimnich • August 14, 2017

The prostate health index or phi test reduces the need for prostate cancer biopsies by 30 percent.

By Gina Chiri-Osmond • July 28, 2017

This week’s Research Roundup highlights postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease.

By Kelley Luedke • July 17, 2017

This week’s Research Roundup highlights oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy.

By Kelley Luedke • June 5, 2017

This week’s Research Roundup highlights the evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers.

By Kelley Luedke • May 29, 2017

This week’s Research Roundup highlights how the androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.

By Kelley Luedke • May 15, 2017

Useful For Assessing the patient’s probability of having detectable prostate cancer when total prostate specific antigen (PSA) concentrations are between 4–10 ng/mL. Results from a[...]

By Mayo Clinic Laboratories • May 9, 2017

Some early-stage cancers are missed by conventional screening and are only detected when symptoms occur. Mayo Clinic is collaborating with Grail, a life science company, and Sutter Health of California, on the STRIVE clinical research study to facilitate the development of Grail’s blood tests for early-stage cancer detection.

By Mayo Clinic Laboratories • May 4, 2017

This week’s Research Roundup highlights the best tumor size cut-points for renal cell carcinoma staging.

By Kelley Luedke • April 24, 2017

This week’s Research Roundup highlights how AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction.

By Kelley Luedke • March 20, 2017

Chromosome analysis, which was once the preferred genetic test for a wide variety of congenital abnormalities, is now one of the most frequently misordered cytogenetic tests at MML. This "Specialty Testing" webinar will outline the differences in technologies and the appropriate use of each test.

By Mayo Clinic Laboratories • February 24, 2017